
    
      Primary objectives:

      1. To examine the efficacy of sitagliptin 100 mg orally daily versus placebo in improving
      hepatic steatosis assessed by magnetic resonance imaging in patients with NAFLD.

      Secondary objectives:

        1. To examine the efficacy of sitagliptin in improving serum AST in patients with NAFLD.

        2. To examine the efficacy of sitagliptin in improving serum ALT in patients with NAFLD.

        3. To examine the efficacy of sitagliptin in improving serum LDL in patients with NAFLD.

        4. To examine the efficacy of sitagliptin in the improvement of insulin sensitivity in
           patients with NAFLD.
    
  